Loring Wolcott & Coolidge Fiduciary Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Sell	3,317 -540	-14%	-$239K	0.02%	135
2026 Q1	$1.68M	Sell	3,857 -121	-3%	-$56.4K	0.02%	130
2025 Q4	$1.89M	Buy	3,978 +28	+0.7%	+$12.1K	0.02%	128
2025 Q3	$1.67M	Buy	3,950 +3,206	+431%	+$1.34M	0.01%	135
2025 Q2	$331K	Buy	744 +50	+7%	+$23K	﹤0.01%	237
2025 Q1	$342K	Hold	694	–	–	﹤0.01%	232
2024 Q4	$308K	Buy	694 +34	+5%	+$15.8K	﹤0.01%	239
2024 Q3	$311K	Buy	660 +101	+18%	+$48.5K	﹤0.01%	235
2024 Q2	$273K	Hold	559	–	–	﹤0.01%	243
2024 Q1	$224K	Buy	559 +12	+2%	+$5.07K	﹤0.01%	261
2023 Q4	$237K	Hold	547	–	–	﹤0.01%	263
2023 Q3	$206K	Hold	547	–	–	﹤0.01%	283
2023 Q2	$192K	Buy	547 +7	+1%	+$2.36K	﹤0.01%	299
2023 Q1	$170K	Buy	540 +145	+37%	+$43.5K	﹤0.01%	288
2022 Q4	$114K	Hold	395	–	–	﹤0.01%	331
2022 Q3	$114K	Hold	395	–	–	﹤0.01%	338
2022 Q2	$111K	Buy	395 +90	+30%	+$24.1K	﹤0.01%	350
2022 Q1	$80K	Hold	305	–	–	﹤0.01%	407
2021 Q4	$67K	Sell	305 -10	-3%	-$1.95K	﹤0.01%	431
2021 Q3	$57K	Sell	315 -25	-7%	-$4.88K	﹤0.01%	450
2021 Q2	$69K	Buy	+340	New	+$71.1K	﹤0.01%	445
2021 Q1	–	Sell	-761	Closed	-$180K	–	696
2020 Q4	$180K	Sell	761 -174	-19%	-$39.9K	﹤0.01%	284
2020 Q3	$254K	Hold	935	–	–	﹤0.01%	245
2020 Q2	$271K	Buy	935 +250	+36%	+$67.8K	﹤0.01%	224
2020 Q1	$163K	Sell	685 -159	-19%	-$36.5K	﹤0.01%	250
2019 Q4	$185K	Hold	844	–	–	﹤0.01%	279
2019 Q3	$143K	Buy	844 +89	+12%	+$15.7K	﹤0.01%	295
2019 Q2	$138K	Hold	755	–	–	﹤0.01%	300
2019 Q1	$139K	Hold	755	–	–	﹤0.01%	292
2018 Q4	$125K	Hold	755	–	–	﹤0.01%	297
2018 Q3	$146K	Hold	755	–	–	﹤0.01%	297
2018 Q2	$128K	Sell	755 -65	-8%	-$10.1K	﹤0.01%	327
2018 Q1	$134K	Hold	820	–	–	﹤0.01%	329
2017 Q4	$123K	Buy	820 +195	+31%	+$28.9K	﹤0.01%	342
2017 Q3	$95K	Hold	625	–	–	﹤0.01%	366
2017 Q2	$95K	Sell	625 -175	-22%	-$21.1K	﹤0.01%	361
2017 Q1	$87K	Hold	800	–	–	﹤0.01%	370
2016 Q4	$59K	Hold	800	–	–	﹤0.01%	377
2016 Q3	$70K	Hold	800	–	–	﹤0.01%	373
2016 Q2	$69K	Hold	800	–	–	﹤0.01%	367
2016 Q1	$64K	Hold	800	–	–	﹤0.01%	363
2015 Q4	$101K	Hold	800	–	–	﹤0.01%	344
2015 Q3	$99K	Hold	800	–	–	﹤0.01%	358
2015 Q2	$99K	Hold	800	–	–	﹤0.01%	358
2015 Q1	$94K	Sell	800 -500	-38%	-$59.9K	﹤0.01%	369
2014 Q4	$154K	Hold	1,300	–	–	﹤0.01%	311
2014 Q3	$146K	Hold	1,300	–	–	﹤0.01%	305
2014 Q2	$123K	Hold	1,300	–	–	﹤0.01%	333
2014 Q1	$92K	Sell	1,300 -177	-12%	-$14K	﹤0.01%	352
2013 Q4	$110K	Buy	1,477 +1,177	+392%	+$82K	﹤0.01%	319
2013 Q3	$23K	Hold	300	–	–	﹤0.01%	430
2013 Q2	$24K	Buy	+300	New	+$22.1K	﹤0.01%	460

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's VRTX Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q2 2026, selling an estimated $239K and leaving 3,317 shares worth $1.65M. The position accounts for 0.02% of the portfolio, ranked #135.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.89M in Q4 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Loring Wolcott & Coolidge Fiduciary Advisors held 3,317 shares of Vertex Pharmaceuticals worth $1.65M as of Q2 2026.
Loring Wolcott & Coolidge Fiduciary Advisors sold 540 Vertex Pharmaceuticals shares in Q2 2026, an estimated $239K.
Vertex Pharmaceuticals made up 0.02% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #135 holding.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Loring Wolcott & Coolidge Fiduciary Advisors's Vertex Pharmaceuticals position peaked at $1.89M in Q4 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.